Klin Onkol 2002; 15(4): 145-147.
Summary: Neoadjuvant chemotherapy has been used as initial treatment in locally advanced breast cancer. The aims of neoadjuvant treatment are:
- Reduction and devitalisation of the primary tumor.
- Decrease of intraoperative tumor cell dissemination.
- Early eradiation of micrometastases by systemic chemotherapy.
- Individual clinical chemotherapy sensitivity testing with the possibility to continue this treatment in responding patients.
53 women with locally advanced breast cancer were treated with neoadjuvant regime: mitoxantrone 12 mg/m
2 1 day, cyclophosphamide 500 mg/m
2 – 1 day, fluorouracile – 500 mg/m
2 1+8 day, every 21 dayĘ three or four cycles. Measurement of tumor by mammography was used to asses the efect of chemotherapy. The response to neoadjuvant chemotherapy: 2 patients with comlete (CR) – 3,8%, 4 patients partiae response (PR) – 7,6%, 47 patients with stable disease (SD) – 88,6%. 69,8% for those having mastectomy and 24,5% for those having breast conservation. Leukopenia was the most frequent hematological toxicity – 1 patients had G4. Nause and vomiting, was the most frequent non-hematological toxicity. I observed mucositis, diarrhoea, cardial toxicity G1-G2, and alopecia, 1 patients G3. The disease – free 5-year survival rate was 58% for all patients.
Full text in PDF
